دورية أكاديمية
أعرض في EDS

Effects of methamphetamine on actigraphy-based sleep parameters in female rhesus monkeys: Orexin receptor mechanisms.

التفاصيل البيبلوغرافية
العنوان: Effects of methamphetamine on actigraphy-based sleep parameters in female rhesus monkeys: Orexin receptor mechanisms.
المؤلفون: Borgatti DA; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS 39216, USA; Graduate Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS 39216, USA., Rowlett JK; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS 39216, USA; Graduate Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS 39216, USA; Center for Innovation and Discovery in Addictions, University of Mississippi Medical Center, Jackson, MS 39216, USA., Berro LF; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS 39216, USA; Graduate Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS 39216, USA; Center for Innovation and Discovery in Addictions, University of Mississippi Medical Center, Jackson, MS 39216, USA. Electronic address: lberro@umc.edu.
المصدر: Drug and alcohol dependence [Drug Alcohol Depend] 2024 Jun 01; Vol. 259, pp. 111285. Date of Electronic Publication: 2024 Apr 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Ireland NLM ID: 7513587 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0046 (Electronic) Linking ISSN: 03768716 NLM ISO Abbreviation: Drug Alcohol Depend Subsets: MEDLINE
أسماء مطبوعة: Publication: Limerick : Elsevier
Original Publication: Lausanne, Elsevier Sequoia.
مواضيع طبية MeSH: Methamphetamine*/pharmacology , Macaca mulatta* , Actigraphy* , Orexin Receptors*/metabolism , Orexin Receptors*/drug effects , Sleep*/drug effects , Sleep*/physiology , Orexin Receptor Antagonists*/pharmacology, Animals ; Female ; Triazoles/pharmacology ; Azepines/pharmacology ; Central Nervous System Stimulants/pharmacology ; Dose-Response Relationship, Drug
مستخلص: Background: The orexin system has been implicated as a mechanism underlying insomnia and methamphetamine-induced sleep disruptions, with a potential role for OX2 receptors in the sleep-modulating effects of orexin. The aim of the present study was to investigate the extent to which orexin receptors mediate the effects of acute methamphetamine administration on actigraphy-based sleep in female rhesus monkeys.
Methods: Actigraphy-based sleep measures were obtained in female rhesus monkeys (n=5) under baseline and acute test conditions. First, morning (10h) i.m. injections of methamphetamine (0.03 - 0.56mg/kg) were administered to determine the effects of methamphetamine alone. Then, saline or methamphetamine (0.3mg/kg) were administered at 10h, and evening (17h30) oral treatments with vehicle, the non-selective orexin receptor antagonist suvorexant (1 - 10mg/kg, p.o.), or the OX2-selective orexin receptor antagonist MK-1064 (1 - 10mg/kg, p.o.) were given. The ability of suvorexant and MK-1064 (10mg/kg, p.o.) to improve actigraphy-based sleep was also assessed in a group of female monkeys quantitatively identified with "short-duration sleep" (n=4).
Results: Methamphetamine dose-dependently disrupted actigraphy-based sleep parameters. Treatment with either suvorexant or MK-1064 dose-dependently improved actigraphy-based sleep in monkeys treated with methamphetamine. Additionally, both suvorexant and MK-1064 promoted actigraphy-based sleep in a group of monkeys with baseline short actigraphy-based sleep.
Conclusions: These findings suggest that orexin-mediated mechanisms play a role in the effects of methamphetamine on actigraphy-based sleep in female monkeys. Targeting the orexin system, in particular OX2 receptors, could be an effective option for treating sleep disruptions observed in individuals with methamphetamine use disorder.
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest.
(Copyright © 2024. Published by Elsevier B.V.)
References: ChemMedChem. 2014 Feb;9(2):311-22. (PMID: 24376006)
Sleep. 2021 May 14;44(5):. (PMID: 33378539)
Neurosci Lett. 2003 May 8;341(3):256-8. (PMID: 12697296)
Med Hypotheses. 2010 May;74(5):928-33. (PMID: 19910125)
Biol Psychiatry. 2019 Jun 1;85(11):925-935. (PMID: 30219208)
Sleep. 2021 Jun 11;44(6):. (PMID: 33406259)
Addict Health. 2019 Jul;11(3):165-172. (PMID: 31839914)
JAMA Psychiatry. 2021 Dec 1;78(12):1329-1342. (PMID: 34550301)
Drug Alcohol Depend. 2008 Apr 1;94(1-3):258-62. (PMID: 18078723)
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):317-323. (PMID: 32214077)
Addiction. 2005 Sep;100(9):1320-9. (PMID: 16128721)
BMC Neurosci. 2013 Aug 28;14:90. (PMID: 23981345)
Neuropharmacology. 2017 Sep 1;123:299-309. (PMID: 28495376)
Addiction. 2010 Oct;105(10):1809-18. (PMID: 20840201)
J Clin Psychiatry. 2013;74 Suppl 1:3-20. (PMID: 24107804)
Brain Res. 2020 Mar 15;1731:145893. (PMID: 30081036)
Sci Rep. 2016 Jun 03;6:27147. (PMID: 27256922)
Drug Alcohol Depend. 2014 Sep 1;142:295-300. (PMID: 25064022)
Curr Psychiatry Rep. 2022 Oct;24(10):509-521. (PMID: 35972717)
Drug Alcohol Depend. 2017 Sep 1;178:291-295. (PMID: 28686987)
PLoS One. 2012;7(7):e39131. (PMID: 22768296)
Sleep Med Clin. 2023 Dec;18(4):511-520. (PMID: 38501523)
J Neurogenet. 2011 Mar;25(1-2):52-61. (PMID: 21473737)
JAMA Psychiatry. 2020 Sep 1;77(9):959-966. (PMID: 32267484)
J Neurosci. 2001 Mar 1;21(5):1656-62. (PMID: 11222656)
J Psychosom Res. 2021 Sep;148:110570. (PMID: 34265497)
Lancet Neurol. 2015 May;14(5):547-58. (PMID: 25895933)
Australas Psychiatry. 2022 Aug;30(4):530-532. (PMID: 35491942)
Psychopharmacology (Berl). 2017 Aug;234(15):2277-2287. (PMID: 28589263)
Forensic Sci Int. 2015 Sep;254:80-6. (PMID: 26197350)
Int J Neuropsychopharmacol. 2021 Jan 20;24(1):54-63. (PMID: 32496559)
Sleep. 2016 Mar 01;39(3):603-12. (PMID: 26943466)
Biol Psychiatry. 2022 Dec 1;92(11):836-844. (PMID: 36328706)
Drug Alcohol Depend. 2021 Oct 1;227:108930. (PMID: 34358767)
Sleep. 2003 Feb 1;26(1):81-5. (PMID: 12627737)
Nat Rev Neurosci. 2007 Mar;8(3):171-81. (PMID: 17299454)
Front Neurosci. 2022 Apr 07;16:866971. (PMID: 35464308)
Curr Top Behav Neurosci. 2017;33:105-136. (PMID: 27909987)
معلومات مُعتمدة: R01 DA011792 United States DA NIDA NIH HHS; F31 DA060673 United States DA NIDA NIH HHS; R00 DA049886 United States DA NIDA NIH HHS; K99 DA049886 United States DA NIDA NIH HHS; R21 DA046778 United States DA NIDA NIH HHS; R01 DA043204 United States DA NIDA NIH HHS
فهرسة مساهمة: Keywords: MK-1064; Methamphetamine; Orexin; Rhesus monkeys; Sleep; Suvorexant
المشرفين على المادة: 0 (suvorexant)
تواريخ الأحداث: Date Created: 20240418 Date Completed: 20240521 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC11111337
DOI: 10.1016/j.drugalcdep.2024.111285
PMID: 38636173
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-0046
DOI:10.1016/j.drugalcdep.2024.111285